Trials / Recruiting
RecruitingNCT07230106
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
A Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of HS-20093 or SHR2554 Tablets in Combination With Novel Hormonal Agents in Participants With Metastatic Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 218 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II, multicentre clinical study investigating HS-20093 or SHR2554 in combination with a Novel Hormonal Agent (NHA) for advanced prostate cancer. The trial comprises two cohorts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HS-20093 for Injection | HS-20093 for injection. |
| DRUG | SHR3680 Tablet | SHR3680 tablet. |
| DRUG | Abiraterone Tablet | Abiraterone tablet. |
| DRUG | SHR2554 Tablet | SHR2554 tablet. |
| DRUG | Enzalutamide Tablet | Enzalutamide tablet. |
| DRUG | Darotamine Capsule | Darotamine capsule. |
Timeline
- Start date
- 2025-12-08
- Primary completion
- 2028-12-01
- Completion
- 2029-12-01
- First posted
- 2025-11-17
- Last updated
- 2026-03-03
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07230106. Inclusion in this directory is not an endorsement.